These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30339819)

  • 1. Generation of cancer vaccine immunogens derived from major histocompatibility complex (MHC) class I molecules using variable epitope libraries.
    Servín-Blanco R; Chávaro-Ortiz RM; Zamora-Alvarado R; Martínez-Cortes F; Gevorkian G; Manoutcharian K
    Immunol Lett; 2018 Dec; 204():47-54. PubMed ID: 30339819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
    NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
    Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin-derived mutant epitopes.
    Domínguez-Romero AN; Martínez-Cortés F; Munguía ME; Odales J; Gevorkian G; Manoutcharian K
    Immunology; 2020 Oct; 161(2):123-138. PubMed ID: 32619293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
    Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K
    Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variable epitope library-based vaccines: shooting moving targets.
    Pedroza-Roldan C; Charles-Niño C; Saavedra R; Govezensky T; Vaca L; Avaniss-Aghajani E; Gevorkian G; Manoutcharian K
    Mol Immunol; 2009 Dec; 47(2-3):270-82. PubMed ID: 19853920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of cancer vaccine immunogens derived from Oncofetal antigen (OFA/iLRP) using variable epitope libraries tested in an aggressive breast cancer model.
    Martínez-Cortés F; Servín-Blanco R; Domínguez-Romero AN; Munguía ME; Guzman Valle J; Odales J; Gevorkian G; Manoutcharian K
    Mol Immunol; 2021 Nov; 139():65-75. PubMed ID: 34454186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor efficacy of MUC1-derived variable epitope library treatments in a mouse model of breast cancer.
    Odales J; Servín-Blanco R; Martínez-Cortés F; Guzman Valle J; Domínguez-Romero AN; Gevorkian G; Manoutcharian K
    Vaccine; 2022 Aug; 40(33):4796-4805. PubMed ID: 35788294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor vaccination in heterozygous congenic F1 mice: presentation of tumor-associated antigen by the two parental class I alleles.
    Carmon L; Tzehoval E; Tirosh B; el-Shami KM; Bar-Haim E; Vadai E; Feldman M; Eisenbach L
    J Immunother; 2000; 23(3):344-52. PubMed ID: 10838663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
    Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
    Front Immunol; 2019; 10():1505. PubMed ID: 31333652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
    Morrison BJ; Steel JC; Morris JC
    BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MMP-7 derived peptides with MHC class-I binding motifs from canine mammary tumor tissue elicit strong antigen-specific T-cell responses in BALB/c mice.
    Yadav PK; Gupta SK; Kumar S; Ghosh M; Yadav BS; Kumar D; Kumar A; Saini M; Kataria M
    Mol Cell Biochem; 2021 Jan; 476(1):311-320. PubMed ID: 32970284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
    Rice J; Buchan S; Stevenson FK
    J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope.
    Huang CH; Peng S; He L; Tsai YC; Boyd DA; Hansen TH; Wu TC; Hung CF
    Gene Ther; 2005 Aug; 12(15):1180-6. PubMed ID: 15800656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis.
    Rai PK; Chodisetti SB; Maurya SK; Nadeem S; Zeng W; Janmeja AK; Jackson DC; Agrewala JN
    J Transl Med; 2018 Oct; 16(1):279. PubMed ID: 30305097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope.
    Raafat N; Sadowski-Cron C; Mengus C; Heberer M; Spagnoli GC; Zajac P
    Int J Cancer; 2012 Sep; 131(5):E659-69. PubMed ID: 22116674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
    Cheng WF; Hung CF; Lee CN; Su YN; Chang MC; He L; Wu TC; Chen CA; Hsieh CY
    Eur J Immunol; 2004 Jul; 34(7):1892-900. PubMed ID: 15214037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
    Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
    Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced tumor immunogenicity through coupling cytokine expression with antigen presentation.
    He X; Tsang TC; Luo P; Zhang T; Harris DT
    Cancer Gene Ther; 2003 Sep; 10(9):669-77. PubMed ID: 12944986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.